Asta Medica, Aktiengesellschaft

Asta Pharma Aktiengesellschaft

Degussa Aktiengesellschaft

Viatris Gmbh & Co Kg

Helmut Hettche

Jurgen Engel

Heinz Ulrich

Reinhard Muckenschnabel

Gerhard Scheffler

Ilona Fleischhauer

Klaus Wessel

Lester Packer

Harald Borbe

Wolfgang Morick

Amira Klip

Hans Bisswanger

Joachim Goede

Werner Sarlikiotis

Carl-Heinrich Weischer

J&uuml;rgen Engel

Matthias Rischer

Peter Emig

Michael Lobisch

Helmut Momberger

Carl H Weischer

Ute Achterrath-Tuckerman

Rudolf Aurich

Axel Kleeman

Hans-Peter Breuel

Ulrich Tibes

Dietmar Gunesch

Wolfgang Brade

Dirk Reischig

Pharmaceutical dosage units containing flupirtine or a pharmaceutically acceptable salt of flupirtine with controlled release of active substance using a delayed-action or controlled-release component. There are 0.001 to 20 parts delayed-action component for each part by weight flupirtine (calculated as the base) and the release rate of flupirtine is between 5 and 300 mg per hour. In some cases, the dosage units may also contain a rapidly releasing component of flupirtine or of one of its salts. The dosage units reduce the sedative effect of flupirtine.

Oral forms of administration containing solid flupirtine with controlled release of active substance

Novel, advantageous dosage forms of thioctic acid and the enantiomers thereof together with thioctic acid salts are described. The pharmaceutical formulations according to the invention are used for the production of pharmaceutical dosage forms which release the active ingredient more rapidly and have greater bioavailability than previous forms.

Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability

Use of R-(&plus;)-&agr;-lipoic acid, R-(&minus;)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

Pharmaceutical compositions and processes for their preparation containing R-&agr;-lipoic acid or S-&agr;-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Pharmaceutical compositions containing R-&agr;-lipoic acid or S-&agr;-lipoic acid as active ingredient

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance. These drugs mentioned can also be used advantageously in combination with other antidiabetic drugs, particularly with insulin, and/or other additives or stabilizers or adjuvants, such as vitamin E, vitamin C, NADH, NADPH and ubiquinone. The invention furthermore relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, as well as their salts, esters and amides for the preparation of drugs for the treatment of diseases with limited function of or a lowered content of the glucose transporters.

Use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid and

Salts of azelastine with acetic acid, gluconic acid, lactic acid or malic acid.

Salts of azelastine having improved solubility effective at treating

The present invention relates to salts of azelastine having improved solubility in water. The salts of the present invention are prepared by reacting azelastine with acetic acid, gluconic acid, lactic acid, or malic acid. The azelastine salts are effective in providing a cytoprotective effect.

Salts of azelastine having improved solubility useful at providing a

Dosage forms containing thioctic acid or solid salts of thioctic acid

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance.

The present invention relates to salts of azelastine having improved solubility in water. The salts of the present invention are prepared by reacting azelastine with acetic acid, gluconic acid, lactic acid or malic acid. A pharmaceutical composition may be prepared containing an azelastine salt and a pharmaceutically-acceptable carrier or diluent therefor. The pharmaceutical composition is useful in the treatment of allergies, asthma, inflammatory and psoriasis disorders and provides a cytoprotective effect.

Salts of azelastine having improved solubility

Pharmaceutical compositions and processes for their preparation containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Pharmaceutical composition containing R-.alpha.-lipoic acid or

Use of R-(+)-.alpha.-lipoic acid, R-(-)dihydrolipoic acid and

Aerosol compressed-gas packages for the administration of biologically active substances with novel suspension stabilizers and propellants which are not harmful to ozone.

Compressed-gas packages using polyoxyethylene glyceryl fatty-acid esters

The invention relates to a drug formulation in the form of tablets containing thioctic acid (.alpha.-lipoic acid) with an active ingredient content between 45% by weight and 99.9% by weight. The invention is characterized in that 20% to 100% of the active ingredient used has a particle size exceeding 100 .mu.m, particulary between 100 .mu.m and 710 .mu.m, preferably 30% to 80% a particle size between 200 .mu.m and 710 .mu.m.

Tablets with thioctic acid of specific particle size

A solid medicinal form having an active substance content of over 45 weight % and a process for its preparation by granulating with large amounts of water, drying and optionally conventional tableting and/or pelleting.

Growing community of inventors

Dietzenbach, Germany

Helmut Hettche